Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices.
1. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol; or a pharmaceutically acceptable salt thereof.
2. An inhaler according to claim 1 , wherein the compound is present as a pharmaceutically acceptable salt which is a α-phenyl cinnamate salt.
3. An inhaler according to claim 1 , wherein the compound is present as a pharmaceutically acceptable salt which is a 1-naphthoate salt.
4. An inhaler according to claim 1 , wherein the compound is present as a pharmaceutically acceptable salt which is an (R)-mandelate salt.
5. An inhaler according to claim 1 , wherein the compound is present in particles ranging in size from 1 μm to 10 μm.
6. An inhaler according to claim 1 , wherein the dry powder formulation comprises lactose.
7. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl) oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol-triphenyl acetate.
8. An inhaler according to claim 7 , wherein the compound is present in particles ranging in size from 1 μm to 10 μm.
9. An inhaler according to claim 7 , wherein the dry powder formulation comprises lactose.